| __timestamp | Corcept Therapeutics Incorporated | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 2043000 |
| Thursday, January 1, 2015 | 1361000 | 3895000 |
| Friday, January 1, 2016 | 2058000 | 6552000 |
| Sunday, January 1, 2017 | 3554000 | 15066000 |
| Monday, January 1, 2018 | 5215000 | 26348000 |
| Tuesday, January 1, 2019 | 5504000 | 33097000 |
| Wednesday, January 1, 2020 | 5582000 | 36272000 |
| Friday, January 1, 2021 | 5281000 | 52873000 |
| Saturday, January 1, 2022 | 5385000 | 57909000 |
| Sunday, January 1, 2023 | 6481000 | 72547000 |
| Monday, January 1, 2024 | 0 |
Unlocking the unknown
In the competitive world of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Exelixis, Inc. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Exelixis has demonstrated a significant increase in cost efficiency, with its cost of revenue growing by approximately 3,450%, from $2.04 million in 2014 to $72.55 million in 2023. In contrast, Corcept's cost of revenue increased by about 635%, from $0.88 million to $6.48 million over the same period.
Exelixis's rapid growth in cost of revenue reflects its expanding operations and market reach, while Corcept's steadier increase suggests a more conservative growth strategy. This comparison highlights the diverse strategies within the biotech sector, offering insights into how companies manage their operational costs to drive profitability.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Corcept Therapeutics Incorporated
Intra-Cellular Therapies, Inc. vs Corcept Therapeutics Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Corcept Therapeutics Incorporated
Cost of Revenue Trends: Exelixis, Inc. vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Galapagos NV
Cost of Revenue Comparison: Exelixis, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and PTC Therapeutics, Inc.
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.